deltatrials
Unknown PHASE3 INTERVENTIONAL 2-arm NCT04335032

EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2

Sponsor: S.L.A. Pharma AG

Conditions SARS-CoV-2
Interventions Eicosapentaenoic acid gastro-resistant capsules Placebo
Updated 7 times since 2020 Last updated: Nov 26, 2021 Started: Jan 8, 2021 Primary completion: Nov 30, 2021 Completion: Dec 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04335032, this PHASE3 trial focuses on SARS-CoV-2 and remains ongoing. Sponsored by S.L.A. Pharma AG, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~May 2020 – ~Dec 2020 · 7 months · monthly snapshotNot Yet Recruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotNot Yet Recruiting~Jan 2022 – ~Dec 2023 · 23 months · monthly snapshotRecruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Dec 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  4. Jan 2022 — Dec 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  5. Jan 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE3

▶ Show 2 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  2. May 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • S.L.A. Pharma AG
Data source: S.L.A. Pharma AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations